CommercialPrior AuthMedium impact
08.01.34d, Exon Skipping Drugs for Duchenne Muscular Dystrophy (DMD) (Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso)), Casimersen (Amondys 45)
Independence Blue Cross·Neurology, Pediatrics, Pharmacy·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes coverage and medical necessity criteria for four exon-skipping drugs used to treat Duchenne Muscular Dystrophy (DMD): Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), and Casimersen (Amondys 45). The policy defines eligibility requirements, prior authorization requirements, and reimbursement guidelines effective January 1, 2025. Billing teams must implement prior authorization workflows and ensure claims meet specified medical necessity criteria.
Action Required
By January 1, 2025: Billing and clinical teams must implement prior authorization requirements for all DMD exon-skipping drug claims (Exondys 51, Vyondys 53, Viltepso, Amondys 45). Update billing system to flag these medications for prior auth review before claim submission. Providers must document medical necessity per policy criteria in patient records. Front desk and authorization staff should reference the policy URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-34d) when processing requests. Claims submitted without required prior authorization and documentation will be denied. Ensure all relevant personnel are trained on the new medical necessity criteria before the effective date.